Published in J Virol on May 01, 2004
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J (2009) 1.32
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One (2013) 1.29
Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol (2005) 1.28
Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J Virol (2005) 1.21
Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One (2008) 1.14
Identification of a novel human immunodeficiency virus type 1 integrase interactor, Gemin2, that facilitates efficient viral cDNA synthesis in vivo. J Virol (2006) 1.08
von Hippel Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. Proc Natl Acad Sci U S A (2007) 1.08
Importin alpha3 interacts with HIV-1 integrase and contributes to HIV-1 nuclear import and replication. J Virol (2010) 1.07
Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core. J Virol (2010) 1.07
Analysis of the viral elements required in the nuclear import of HIV-1 DNA. J Virol (2009) 1.05
Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import. Retrovirology (2005) 1.04
The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol (2012) 1.03
Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteins. J Virol (2006) 1.03
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem (2009) 1.03
Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription. Viruses (2009) 1.03
Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol (2007) 1.03
A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J Comput Aided Mol Des (2005) 1.02
Mutations affecting interaction of integrase with TNPO3 do not prevent HIV-1 cDNA nuclear import. Retrovirology (2011) 1.01
Augmentation of reverse transcription by integrase through an interaction with host factor, SIP1/Gemin2 Is critical for HIV-1 infection. PLoS One (2009) 0.99
Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase. Retrovirology (2009) 0.99
Sequential deletion of the integrase (Gag-Pol) carboxyl terminus reveals distinct phenotypic classes of defective HIV-1. J Virol (2011) 0.97
Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J Biol Chem (2011) 0.95
Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication. PLoS Pathog (2009) 0.95
HIV-1 replication in cell lines harboring INI1/hSNF5 mutations. Retrovirology (2006) 0.92
Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors. Expert Rev Mol Med (2013) 0.92
A novel function for spumaretrovirus integrase: an early requirement for integrase-mediated cleavage of 2 LTR circles. Retrovirology (2005) 0.92
Role of integrase in reverse transcription of the Saccharomyces cerevisiae retrotransposon Ty1. Eukaryot Cell (2005) 0.91
Retroviral DNA Integration. Chem Rev (2016) 0.90
Cooperation between reverse transcriptase and integrase during reverse transcription and formation of the preintegrative complex of Ty1. Eukaryot Cell (2006) 0.86
Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein. J Virol (2015) 0.85
Analysis of HIV-1 replication block due to substitutions at F61 residue of reverse transcriptase reveals additional defects involving the RNase H function. Nucleic Acids Res (2006) 0.84
Peptide HIV-1 integrase inhibitors from HIV-1 gene products. J Med Chem (2010) 0.83
A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA. Virus Res (2012) 0.83
Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles. J Virol (2007) 0.82
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors. J Virol (2014) 0.82
Mechanisms and inhibition of HIV integration. Drug Discov Today Dis Mech (2006) 0.82
The self primer of the long terminal repeat retrotransposon Tf1 is not removed during reverse transcription. J Virol (2006) 0.81
Changes in the accessibility of the HIV-1 Integrase C-terminus in the presence of cellular proteins. Retrovirology (2010) 0.81
INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo. Retrovirology (2013) 0.79
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations. Antimicrob Agents Chemother (2015) 0.78
Interaction between Reverse Transcriptase and Integrase Is Required for Reverse Transcription during HIV-1 Replication. J Virol (2015) 0.78
Targeting human immunodeficiency virus type 1 assembly, maturation and budding. Drug Target Insights (2007) 0.77
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions. Antimicrob Agents Chemother (2015) 0.77
Retroviral Integrase: Then and Now. Annu Rev Virol (2015) 0.77
Retroviral DNA Transposition: Themes and Variations. Microbiol Spectr (2014) 0.76
Coevolutionary Analysis Identifies Protein-Protein Interaction Sites between HIV-1 Reverse Transcriptase and Integrase. Virus Evol (2016) 0.75
Molecular Docking and Molecular Dynamics to Identify a Novel Human Immunodeficiency Virus Inhibitor from Alkaloids of Toddalia asiatica. Pharmacogn Mag (2015) 0.75
Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies. Bioorg Med Chem (2010) 0.75
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Structural dynamics of native and V260E mutant C-terminal domain of HIV-1 integrase. J Comput Aided Mol Des (2015) 0.75
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A (1993) 9.47
Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. Cell (1993) 8.99
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A (1993) 6.44
Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science (1994) 5.47
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science (1991) 5.42
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J (1993) 4.39
Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol (2001) 3.66
Complementation between HIV integrase proteins mutated in different domains. EMBO J (1993) 3.32
Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J (1991) 2.97
Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol (1996) 2.82
Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci U S A (1994) 2.47
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem (1994) 2.28
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. J Virol (1999) 2.13
HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res (1999) 2.06
Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro. Biochemistry (1996) 1.84
Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry (1998) 1.83
An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. J Biol Chem (1995) 1.67
Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system. Proc Natl Acad Sci U S A (1993) 1.65
Murine leukemia virus pol gene products: analysis with antisera generated against reverse transcriptase and endonuclease fusion proteins expressed in Escherichia coli. J Virol (1986) 1.55
Multimerization determinants reside in both the catalytic core and C terminus of avian sarcoma virus integrase. J Biol Chem (1995) 1.35
Contributions of DNA polymerase subdomains to the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1994) 1.21
Folding of the multidomain human immunodeficiency virus type-I integrase. Protein Sci (1994) 1.20
HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other. FEBS Lett (2001) 1.17
Epitope mapping of HIV-1 reverse transcriptase with monoclonal antibodies that inhibit polymerase and RNase H activities. J Acquir Immune Defic Syndr (1992) 1.12
2.2 A resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains). Structure (1994) 1.09
Kinetic analysis of template.primer interactions with recombinant forms of HIV-1 reverse transcriptase. Biochemistry (1993) 1.03
Sequences in the human immunodeficiency virus type 1 U3 region required for in vivo and in vitro integration. J Virol (1995) 1.02
Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases. Biochem J (2002) 0.95
Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase. Virology (1999) 0.89
Subcellular localization and integration activities of rous sarcoma virus reverse transcriptase. J Virol (2002) 0.89
Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase. J Virol (1999) 0.87
The alpha and beta chains of avian retrovirus reverse transcriptase independently expressed in Escherichia coli: characterization of enzymatic activities. Proc Natl Acad Sci U S A (1988) 0.86
Biochemical characterization of the p51 sub-unit of human immunodeficiency virus reverse transcriptase in homo- and heterodimeric recombinant forms of the enzyme. FEBS Lett (1992) 0.79
Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol (2002) 2.15
Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol (2004) 1.85
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci U S A (2005) 1.48
HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci (2008) 1.37
The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol (2007) 1.29
Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rγ(-/-) (NSG) BLT mice. Virology (2011) 1.23
A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: implications for tumorigenesis. EMBO J (2002) 1.21
RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol (2010) 1.18
Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance. J Virol (2004) 1.14
Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology (2013) 1.09
Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection. Retrovirology (2008) 1.08
Human telomerase RNA template sequence is a determinant of telomere repeat extension rate. J Biol Chem (2005) 1.06
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One (2007) 1.06
Aptamers directed to HIV-1 reverse transcriptase display greater efficacy over small hairpin RNAs targeted to viral RNA in blocking HIV-1 replication. Mol Ther (2005) 1.03
Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res (2008) 1.02
Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates. Int J Biochem Cell Biol (2004) 1.01
Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. Cancer Res (2011) 1.00
Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication. J Virol (2002) 0.99
Multimerization and DNA binding properties of INI1/hSNF5 and its functional significance. J Biol Chem (2009) 0.96
Substitutions at Phe61 in the beta3-beta4 hairpin of HIV-1 reverse transcriptase reveal a role for the Fingers subdomain in strand displacement DNA synthesis. J Mol Biol (2003) 0.96
INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors. Clin Cancer Res (2007) 0.96
Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication. PLoS Pathog (2009) 0.95
Substitutions of Phe61 located in the vicinity of template 5'-overhang influence polymerase fidelity and nucleoside analog sensitivity of HIV-1 reverse transcriptase. J Biol Chem (2002) 0.94
Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection. J Mol Biol (2006) 0.92
Dynamics of virus-host interplay in HIV-1 replication. Curr HIV Res (2006) 0.92
Mutations proximal to the minor groove-binding track of human immunodeficiency virus type 1 reverse transcriptase differentially affect utilization of RNA versus DNA as template. J Virol (2003) 0.92
HIV-1 replication in cell lines harboring INI1/hSNF5 mutations. Retrovirology (2006) 0.92
Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1. Proc Natl Acad Sci U S A (2010) 0.90
The telomerase-specific T motif is a restrictive determinant of repetitive reverse transcription by human telomerase. Mol Cell Biol (2009) 0.89
Examining interactions of HIV-1 reverse transcriptase with single-stranded template nucleotides by nucleoside analog interference. J Biol Chem (2006) 0.88
The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity. Nucleic Acids Res (2007) 0.88
Design and synthesis of 4-HPR derivatives for rhabdoid tumors. Bioorg Med Chem Lett (2008) 0.88
Genetic characterization of HIV type 1 Tat exon 1 from a southern Indian clinical cohort: identification of unique epidemiological signature residues. AIDS Res Hum Retroviruses (2012) 0.88
Structural determinants of slippage-mediated mutations by human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem (2006) 0.87
Inhibition of early stages of HIV-1 assembly by INI1/hSNF5 transdominant negative mutant S6. J Virol (2010) 0.87
Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors. Bioorg Med Chem Lett (2008) 0.86
Influence of naturally occurring insertions in the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and mutation frequencies in vitro. J Gen Virol (2006) 0.84
Methods to study monocyte migration induced by HIV-infected cells. Methods Mol Biol (2009) 0.84
Analysis of HIV-1 replication block due to substitutions at F61 residue of reverse transcriptase reveals additional defects involving the RNase H function. Nucleic Acids Res (2006) 0.84
Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients. AIDS (2014) 0.83
Probing the active site steric flexibility of HIV-1 reverse transcriptase: different constraints for DNA- versus RNA-templated synthesis. Biochemistry (2008) 0.83
HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors. AIDS Res Ther (2005) 0.82
Structural features of mouse telomerase RNA are responsible for the lower activity of mouse telomerase versus human telomerase. Biochem J (2006) 0.82
Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer (2010) 0.82
K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies. J Mol Biol (2010) 0.81
Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptase. PLoS One (2008) 0.80
Analysis of 2-LTR circle junctions of viral DNA in infected cells. Methods Mol Biol (2009) 0.80
Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication. Retrovirology (2008) 0.79
Reverse two-hybrid screening to analyze protein-protein interaction of HIV-1 viral and cellular proteins. Methods Mol Biol (2009) 0.79
Instability of retroviral vectors with HIV-1-specific RT aptamers due to cryptic splice sites in the U6 promoter. AIDS Res Ther (2007) 0.79
INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo. Retrovirology (2013) 0.79
Impaired surfactant production by alveolar epithelial cells in a SCID-hu lung mouse model of congenital human cytomegalovirus infection. J Virol (2012) 0.78
In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines. Cancer Cell Int (2011) 0.78
Lys66 residue as a determinant of high mismatch extension and misinsertion rates of HIV-1 reverse transcriptase. FEBS J (2012) 0.77
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2012) 0.76
Phylogenetic characterization of six full-length HIV-1 subtype C molecular clones from three patients: identification of rare subtype C strains containing two NF-κB motifs in the long terminal repeat. AIDS Res Hum Retroviruses (2014) 0.75
Association of a 3' Untranslated Region Polymorphism in PCSK9 with HIV Viral Load and CD4+ Levels in HIV/Hepatitis C Virus Co-Infected Women. AIDS (2017) 0.75